Search results
Meet Moderna. Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines. Learn more about us. Join us and change the world of medicine. Life at Moderna. So, what is mRNA? Messenger RNA (mRNA) already exists in your body. It carries a “message” - instructions that direct your cells what to do.
Mar 26, 2024 · The NEXTCove clinical trial is a randomized, observer-blind, active-controlled study of approximately 11,400 individuals aged 12 years and older in the United States, United Kingdom and Canada. mRNA-1283 was found to have a similar safety profile to Moderna's approved COVID-19 vaccines.
We’re making biotech history. Since 2010, we have worked to build the industry's leading mRNA technology platform. Learn more about Moderna’s history.
Sep 11, 2023 · Moderna's updated COVID-19 vaccine contains spike proteins for the XBB.1.5 sublineage of SARS-CoV-2 to help prevent COVID-19 in individuals 6 months of age and older. With the U.S. FDA's decision, Moderna will begin shipping doses to vaccination sites across the U.S., with updated vaccines expected to be available in the coming days.
Sep 6, 2023 · Clinical trial data from research assay confirmed Moderna's updated COVID-19 vaccine showed an 8.7 to 11-fold increase in neutralizing antibodies against circulating variants, including BA.2.86, EG.5, and FL.1.5.1 variants
- www.who.int
- › Newsroom
- › Feature stories
- › Detail
Aug 18, 2022 · The Moderna vaccine after two doses and a first booster dose has been shown to have very high effectiveness against severe disease, hospitalizations and death, and modest effectiveness against symptomatic illness.
Nov 1, 2023 · Information about Moderna COVID-19 Vaccine, Bivalent. Updated, bivalent mRNA COVID-19 vaccines are now FDA-authorized for all doses for individuals ages 6 months and older.
Jan 31, 2022 · Moderna’s Covid-19 vaccine has received full approval from the US Food and Drug Administration, according to news releases from the FDA and Moderna. The vaccine, named Spikevax, is now approved...
Oct 4, 2023 · mRNA-1083 showed strong immunogenicity against influenza and COVID-19, with an acceptable reactogenicity and safety profile, compared to licensed standalone vaccines. Company to begin Phase 3 trial of mRNA-1083 in adults 50 years and above.
Apr 11, 2023 · Moderna's approach to ease the global burden of respiratory infections includes vaccine candidates against major causative pathogens, including SARS-CoV-2, influenza virus, and respiratory syncytial virus (RSV).
